240 related articles for article (PubMed ID: 15001160)
1. Local delivery of poxvirus vaccines for melanoma.
Hörig H; Kaufman HL
Semin Cancer Biol; 2003 Dec; 13(6):417-22. PubMed ID: 15001160
[TBL] [Abstract][Full Text] [Related]
2. Manipulating the local tumor microenvironment with poxviruses expressing costimulatory molecules.
Kaufman HL
Ann N Y Acad Sci; 2005 Dec; 1062():41-50. PubMed ID: 16461787
[TBL] [Abstract][Full Text] [Related]
3. Induction of an antigen cascade by diversified subcutaneous/intratumoral vaccination is associated with antitumor responses.
Kudo-Saito C; Schlom J; Hodge JW
Clin Cancer Res; 2005 Mar; 11(6):2416-26. PubMed ID: 15788693
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy of melanoma.
Parmiani G; Castelli C; Rivoltini L; Casati C; Tully GA; Novellino L; Patuzzo A; Tosi D; Anichini A; Santinami M
Semin Cancer Biol; 2003 Dec; 13(6):391-400. PubMed ID: 15001157
[TBL] [Abstract][Full Text] [Related]
5. [General principles and first clinical trials of therapeutic vaccines against cancer].
Baurain JF; Van der Bruggen P; Van den Eynde BJ; Coulie PG; Van Baren N
Bull Cancer; 2008 Mar; 95(3):327-35. PubMed ID: 18390413
[TBL] [Abstract][Full Text] [Related]
6. Melanoma cancer vaccines and anti-tumor T cell responses.
Vujanovic L; Butterfield LH
J Cell Biochem; 2007 Oct; 102(2):301-10. PubMed ID: 17647270
[TBL] [Abstract][Full Text] [Related]
7. Dendritic cells loaded with killed allogeneic melanoma cells can induce objective clinical responses and MART-1 specific CD8+ T-cell immunity.
Palucka AK; Ueno H; Connolly J; Kerneis-Norvell F; Blanck JP; Johnston DA; Fay J; Banchereau J
J Immunother; 2006; 29(5):545-57. PubMed ID: 16971810
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of melanoma vaccines with molecularly defined antigens by ex vivo monitoring of tumor-specific T cells.
Speiser DE; Pittet MJ; Rimoldi D; Guillaume P; Luescher IF; Liénard D; Lejeune F; Cerottini JC; Romero P
Semin Cancer Biol; 2003 Dec; 13(6):461-72. PubMed ID: 15001165
[TBL] [Abstract][Full Text] [Related]
9. Melanoma vaccines.
Chapman PB
Semin Oncol; 2007 Dec; 34(6):516-23. PubMed ID: 18083375
[TBL] [Abstract][Full Text] [Related]
10. Pox viral vaccine approaches.
Arlen PM; Kaufman HL; DiPaola RS
Semin Oncol; 2005 Dec; 32(6):549-55. PubMed ID: 16338420
[TBL] [Abstract][Full Text] [Related]
11. Vaccine therapy for melanoma: current status and future directions.
Terando AM; Faries MB; Morton DL
Vaccine; 2007 Sep; 25 Suppl 2():B4-16. PubMed ID: 17646038
[TBL] [Abstract][Full Text] [Related]
12. Immune monitoring of T-cell responses in cancer vaccine development.
Keilholz U; Martus P; Scheibenbogen C
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2346s-2352s. PubMed ID: 16609057
[TBL] [Abstract][Full Text] [Related]
13. Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine.
Sondak VK; Sosman JA
Semin Cancer Biol; 2003 Dec; 13(6):409-15. PubMed ID: 15001159
[TBL] [Abstract][Full Text] [Related]
14. Clinical phase I intratumoral administration of two recombinant ALVAC canarypox viruses expressing human granulocyte-macrophage colony-stimulating factor or interleukin-2: the transgene determines the composition of the inflammatory infiltrate.
Hofbauer GF; Baur T; Bonnet MC; Tartour E; Burg G; Berinstein NL; Dummer R
Melanoma Res; 2008 Apr; 18(2):104-11. PubMed ID: 18337646
[TBL] [Abstract][Full Text] [Related]
15. Dendritic cell vaccines in melanoma: from promise to proof?
Lesterhuis WJ; Aarntzen EH; De Vries IJ; Schuurhuis DH; Figdor CG; Adema GJ; Punt CJ
Crit Rev Oncol Hematol; 2008 May; 66(2):118-34. PubMed ID: 18262431
[TBL] [Abstract][Full Text] [Related]
16. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.
Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO
Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479
[TBL] [Abstract][Full Text] [Related]
17. Allogeneic and autologous melanoma vaccines: where have we been and where are we going?
Sondak VK; Sabel MS; Mulé JJ
Clin Cancer Res; 2006 Apr; 12(7 Pt 2):2337s-2341s. PubMed ID: 16609055
[TBL] [Abstract][Full Text] [Related]
18. Local delivery of recombinant vaccinia virus expressing secondary lymphoid chemokine (SLC) results in a CD4 T-cell dependent antitumor response.
Flanagan K; Glover RT; Hörig H; Yang W; Kaufman HL
Vaccine; 2004 Jul; 22(21-22):2894-903. PubMed ID: 15246626
[TBL] [Abstract][Full Text] [Related]
19. Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine.
Hsueh EC; Morton DL
Semin Cancer Biol; 2003 Dec; 13(6):401-7. PubMed ID: 15001158
[TBL] [Abstract][Full Text] [Related]
20. Strategies to enhance the therapeutic activity of cancer vaccines: using melanoma as a model.
Berinstein NL
Ann N Y Acad Sci; 2009 Sep; 1174():107-17. PubMed ID: 19769743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
